| 000 | 01164 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517125359.0 | ||
| 264 | 0 | _c20171009 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a1532-1924 | ||
| 024 | 7 |
_a10.1016/j.beha.2016.10.009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLitzow, Mark R | |
| 245 | 0 | 0 |
_aShould anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission? _h[electronic resource] |
| 260 |
_bBest practice & research. Clinical haematology _c12 2016 |
||
| 300 |
_a345-350 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAllografts |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xtherapeutic use |
| 650 | 0 | 4 | _aPhiladelphia Chromosome |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xtherapy |
| 773 | 0 |
_tBest practice & research. Clinical haematology _gvol. 29 _gno. 4 _gp. 345-350 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.beha.2016.10.009 _zAvailable from publisher's website |
| 999 |
_c26642795 _d26642795 |
||